135 related articles for article (PubMed ID: 33470162)
1. Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
Visacri MB; Duarte NC; Lima TM; de Souza RN; Cobaxo TS; Teixeira JC; Barbosa CR; Dias LP; Tavares MG; Pincinato EC; Lima CS; Moriel P
J Oncol Pharm Pract; 2022 Mar; 28(2):326-336. PubMed ID: 33470162
[TBL] [Abstract][Full Text] [Related]
2. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
[TBL] [Abstract][Full Text] [Related]
3. Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Winterhalder R; Hoesli P; Delmore G; Pederiva S; Bressoud A; Hermann F; von Moos R;
Oncology; 2011; 80(1-2):29-33. PubMed ID: 21606661
[TBL] [Abstract][Full Text] [Related]
4. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Zahrina AK; Norsa'adah B; Hassan NB; Norazwany Y; Norhayati I; Roslan MH; Wan Nazuha WR
Asian Pac J Cancer Prev; 2014; 15(21):9225-32. PubMed ID: 25422205
[TBL] [Abstract][Full Text] [Related]
5. Adherence and safety study in patients on treatment with capecitabine.
Fernández-Ribeiro F; Olivera-Fernández R; Crespo-Diz C
Farm Hosp; 2017 Mar; 41(2):204-221. PubMed ID: 28236798
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
7. Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer.
Kawakami K; Yokokawa T; Kobayashi K; Sugisaki T; Suzuki K; Suenaga M; Yamaguchi K; Inoue A; Machida Y; Yamaguchi T; Hama T
Oncol Res; 2017 Nov; 25(9):1625-1631. PubMed ID: 28766482
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Hofheinz RD; Heinemann V; von Weikersthal LF; Laubender RP; Gencer D; Burkholder I; Hochhaus A; Stintzing S
Br J Cancer; 2012 Nov; 107(10):1678-83. PubMed ID: 23033005
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
[TBL] [Abstract][Full Text] [Related]
10. Analysis of data on capecitabine-related adverse drug reactions from the Korean adverse event reporting system database.
Park JY
Eur J Oncol Nurs; 2018 Jun; 34():55-60. PubMed ID: 29784139
[TBL] [Abstract][Full Text] [Related]
11. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
[No Abstract] [Full Text] [Related]
12. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
[TBL] [Abstract][Full Text] [Related]
13. Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.
Wang L; Liu Y; Yin X; Fang W; Xiong J; Zhao B; Zhang M; Zou Y; Qiu H; Yuan X
JAMA Netw Open; 2020 Jul; 3(7):e2011036. PubMed ID: 32687588
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Hong YS; Song SY; Lee SI; Chung HC; Choi SH; Noh SH; Park JN; Han JY; Kang JH; Lee KS; Cho JY
Ann Oncol; 2004 Sep; 15(9):1344-7. PubMed ID: 15319239
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Ison G; Beaver JA; McGuinn WD; Palmby TR; Dinin J; Charlab R; Marathe A; Jin R; Liu Q; Chen XH; Ysern X; Stephens O; Bai G; Wang Y; Dorff SE; Cheng J; Tang S; Sridhara R; Pierce W; McKee AE; Ibrahim A; Kim G; Pazdur R
Clin Cancer Res; 2016 Sep; 22(18):4545-9. PubMed ID: 27401247
[TBL] [Abstract][Full Text] [Related]
18. Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis.
Kawakami K; Nakamoto E; Yokokawa T; Sugita K; Mae Y; Hagino A; Suenaga M; Mizunuma N; Oniyama S; Machida Y; Yamaguchi T; Hama T
Patient Prefer Adherence; 2015; 9():561-7. PubMed ID: 25914526
[TBL] [Abstract][Full Text] [Related]
19. A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.
Gratiaux J; Gossery C; Rezzag-Mahcene C; Botsen D; Visseaux L; Slimano F; Bouche O
J Oncol Pharm Pract; 2022 Jan; 28(1):247-249. PubMed ID: 34233543
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
